EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction



Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction



Clinical Therapeutics 20(6): 1033-1048



Sildenafil citrate, an oral therapy for erectile dysfunction, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the predominant isozyme metabolizing cGMP in the corpus cavernosum. Chemically, it is a compound of the pyrazolo-pyrimidinyl-methylpiperazine class. Sildenafil has no direct relaxant effect on human corpus cavernosum but enhances the relaxant effect of nitric oxide (NO) on the corpus cavernosum by inhibiting PDE5, which is responsible for degradation of cGMP in this tissue. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil increases concentrations of cGMP in the corpus cavernosum, causing smooth muscle relaxation and blood flow into the penis, resulting in an erection. Sildenafil at recommended doses has no effect in the absence of sexual stimulation. The drug is rapidly absorbed after oral administration, with absolute bioavailability of 40%. Its pharmacokinetics are dose proportional over the recommended dosage range. Maximum plasma concentrations are reached within 30 to 120 minutes after oral dosing in the fasting state. Sildenafil is cleared predominantly by the hepatic microsomal isoenzymes CYP3A4 (major route) and CYP2C9 (minor route). Clinical studies assessed the effect of sildenafil on the ability of men with erectile dysfunction to engage in sexual activity and, specifically, to achieve and maintain an erection sufficient for satisfactory sexual intercourse. Sildenafil was evaluated at doses of 25, 50, and 100 mg in randomized, double-masked, placebo-control clinical trials of up to 6 months' duration. The drug was administered to hundreds of patients aged 19 to 87 years having erectile dysfunction of various etiologies for a mean duration of 5 years. Sildenafil was associated with statistically significant improvement in erectile function compared with placebo. Adverse effects reported at a rate of >2% were headache, flushing, dyspepsia, nasal congestion, urinary tract infection, abnormal vision, diarrhea, dizziness, and rash. No cases of priapism were reported. The use of sildenafil is contraindicated in men who are taking organic nitrates, because of the potential for a precipitous decrease in blood pressure. Postmarketing reports and surveillance have revealed at least 39 deaths with sildenafil use in men having a history of heart disease, men taking nitrate medications, and men in poor physical health due to lack of exercise. Many of the men who experienced serious adverse effects or death had a variety of concomitant diseases and were taking multiple medications.

(PDF emailed within 0-6 h: $19.90)

Accession: 011321662

Download citation: RISBibTeXText

DOI: 10.1016/s0149-2918(98)80103-3



Related references

Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clinical Therapeutics 20(6): 1033-1048, 1999

Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. British Journal of Psychiatry 178(April): 325-330, April, 2001

Safety and efficacy of China-made sildenafil citrate in the treatment of erectile dysfunction. Zhonghua Nan Ke Xue 23(1): 43-48, 2018

Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. International Journal of Clinical Practice 55(3): 171-176, 2001

The efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with comorbid depression. JGIM 14(SUPPL 2): 72, April, 1999

Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. Journal of Urology 164(4): 1192-1196, October, 2000

Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. American Journal of Cardiology 83(5A): 29C-34C, March 4, 1999

Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. International Journal of Impotence Research 13(5): 261-267, 2002

Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. Journal of Andrology 22(5): 793-797, 2001

Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with diabetes mellitus Results from 2 European studies. Diabetes 50(Supplement 2): A91, June, 2001

Sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction: a 12-week, flexible-dose study to assess efficacy and safety. International Journal of Clinical Practice. Supplement 102: 6-7, 2000

Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. International Journal of Impotence Research 12(3): 177-182, 2000

Sildenafil citrate (Viagra) efficacy in the treatment of erectile dysfunction in patients with common concomitant conditions. Sildenafil Study Group. International Journal of Clinical Practice. Supplement 102: 21-23, 2000

Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. American Journal of Cardiology 95(1): 36-42, 2004

Efficacy and safety of sildenafil citrate in men with erectile dysfunction who are taking multiple antihypertensives. European Heart Journal 23(Abstract Supplement): 211, August-September, 2002